CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma...

menu
menu